This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

1. A use of an insulin sensitiser an insulin secretagogue and a biguanide antihyperglycaemic agent as a pharmaceutically acceptable carrier therefor for use as an active therapeutic substance for treating diabetes mellitus and conditions associated with diabetes mellitus wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound I) which comprises the administration of 2 to 12 mg of said Compound. 2. The use according to claim 1 wherein ...

PURPOSE: To obtain a therapeutic agent for Parkinson's regressive neuropathy.CONSTITUTION: This composition for treating intracerebral neuropathy due to hypoxia consists of a medicinal agent to block the ATP-sensitive potassium channel of the brain selected from quinine and sulfonylurea-based medicinal agents such as tolbutamide glyburide and chlorpropamide.COPYRIGHT: (C)1992JPO

This invention relates to a therapeutic preparation comprising ferric ammonium citrate and zinc oxide and, optionally, aspirin, sodium bicarbonate, citric acid, chlorpropamide and/or Vitamin B1, to a method of preparing it and to a method of treating a diseased mammal, comprising administering to the diseased mammal a pharmaceutically effective amount of the therapeutic preparation.

Certain novel oral antidiabetic compositions are disclosed. These pharmaceutical compositions involve the concomitant use of two different organic chemical compounds each chosen from a separate class of known hypoglycemic agents. One class of agents involves certain known oxazolidine-24-dione compounds (A) while the other class is primarily concerned with a series of known hypoglycemic sulfonylureas (B). Preferred embodiments involve the use of 5-(3-thienyl)oxazolidine-24-dione 5-(4-ethoxy-3-thi...

Certain novel oral antidiabetic compositions are disclosed. These pharmaceutical compositions involve the concomitant use of two different organic chemical compounds each chosen from a separate class of known hypoglycemic agents. One class of agents involves certain known oxazolidine-2,4-dione compounds (A), while the other class is primarily concerned with a series of known hypoglucemic sulfonylureas (B). Preferred embodiments involve the use of 5-(3-thienyl)oxazolidine-2,4-dione, 5-(4-ethoxy-3...

Certain novel oral antidiabetic compositions are disclosed. These pharmaceutical compositions involve the concomitant use of two different organic chemical compounds each chosen from a separate class of known hypoglycemic agents. One class of agents involves certain known oxazolidine-2,4-dione compounds (A), while the other class is primarily concerned with a series of known hypoglycemic sulfonylureas (B). Preferred embodiments involve the use of 5-(3-thienyl)oxazolidine-2,4-dione, 5-(4-ethoxy-3...

1535203 Hypolipidemic agents SMITHKLINE CORP 26 Nov 1975 [27 Nov 1974] 44565/75 Heading A5B A pharmaceutical composition in dosage unit form comprises 4-(2-thenoyl)-2, 3-dichlorophenoxyacetic acid, or its pharmaceutically acceptable salts in a dosage unit range of 100 mg to 500 mg, in combination with a second active medicinal ingredient which is a second hypolipidemic agent or an agent which does not reduce plasma lipid levels but is used to treat a disease or abnormal condition in which hyperl...

Novel mono-alkyl substituted and dialkyl substituted 2-alkyl-5-carbamoyl pyrazines are prepared by reacting a 2-alkyl-5-carboxy-pyrazine with a monoalkyl amine or dialkyl amine respectively where the alkyl groups contain 1 to 4 C atoms. The invention also includes 2,5-dimethyl pyrazine p-toluene sulphonate and its preparation by reacting 2,5-dimethyl pyrazine with p-toluene-sulphonic acid, and the salts of the above carbamoyl derivatives. The compounds have therapeutic properties. The preparatio...